Week in Review: Key COVID-19 updates | Stem cell therapy and heart attacks | Risk of death from stroke drops 24%

The COVID-19 pandemic has changed the practice of cardiology as we know it, leading to supplies shortages, delayed procedures, and an at-risk patient population fearful of the road ahead. How has the outbreak affected cath labs?

Patients with cardiovascular disease should continue taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) as prescribed if they are diagnosed with the new coronavirus (COVID-19), according to a joint statement from three medical societies. 

A California judge is recommending that a University of California, Los Angeles cardiologist accused of sexually assaulting three women have his medical license revoked.

The Mayo Clinic researchers were "surprised" at how far the intervention restored the diseased hearts back to normal.

The American Heart Association (AHA) has shared a detailed account of its role as the world continues to fight against the spread of the new coronavirus.

The British Heart Foundation (BHF) has published a statement warning patients with certain medical conditions, including cardiovascular diseases, to be “extra vigilant” as the new coronavirus continues to spread.

Heart patients with implanted left ventricular assist devices are more likely to both attempt and succeed in committing suicide than other chronically ill patients, according to a study out of France.

The presence of mental stress is a key predictor of when MI patients may have a repeat MI or die from heart disease, according to new research highlighted by the American College of Cardiology.

The primary reason behind this change is believed to be significant improvements in how healthcare providers care for stroke patients. 

The FDA has published new requirements for the health warnings featured on cigarette packages and in cigarette advertisements.